New shot could replace IV drips for nerve disease patients
NCT ID NCT06637072
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether adults with CIDP, a nerve disorder causing weakness and numbness, could safely switch from regular intravenous immunoglobulin (IVIg) infusions to a new injectable drug called efgartigimod PH20 SC. Twenty-three participants who were stable on IVIg were given the new drug as a shot under the skin for 12 weeks. The main goal was to see how many could stay on the new treatment without needing to go back to IVIg.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
efgartigimod PH20 SC (a biologic drug given as a shot under the skin)
What this could lead to
If this works, it could offer people with CIDP a more convenient treatment option that requires fewer clinic visits than regular IV infusions.
What could go wrong
This is a small, early-phase study with only 23 participants and no comparison group. Results may not apply to everyone with CIDP, and side effects or lack of effectiveness could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedar Health Research - Dallas
Dallas, Texas, 75251, United States
-
Erlanger Neuroscience Institute
Chattanooga, Tennessee, 37403, United States
-
Horizon Clinical Research: Gill Neuroscience
Cypress, Texas, 21216, United States
-
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
-
National Neuromuscular Research Institute
Austin, Texas, 78759, United States
-
Neurology Associates PA
Maitland, Florida, 32751, United States
-
Northwest Houston Neurology - Cypress
Cypress, Texas, 77429, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
SRI International - ClinEdge
Plymouth, Michigan, 48170, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Velocity Clinical Research
Lafayette, Louisiana, 70508, United States
-
Velocity Clinical Research
Raleigh, North Carolina, 27607, United States
-
Visionary Investigators Network
Miami, Florida, 33180, United States